Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed 4-1BB-CD3ζ CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Glofitamab (Primary) ; Mosunetuzumab (Primary) ; Obinutuzumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 12 Feb 2025 Planned End Date changed from 31 Dec 2025 to 30 Jun 2027.
- 12 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 30 Jun 2026.
- 03 May 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.